Activity Overview
Low-grade serous ovarian cancer (LGSOC) is a rare, distinct subtype of epithelial ovarian cancer that disproportionately affects younger women and remains challenging to treat due to its slow progression, high recurrence risk, and limited responsiveness to chemotherapy. With the rapidly evolving landscape of targeted therapies—including recent advances in RAF/MEK pathway inhibitors—clinicians face increasing complexity in diagnosis, molecular interpretation, and treatment selection, highlighting a significant unmet educational need.
To address these gaps, this program uses the Cases and Conversations™ format to deliver an interactive, case-based discussion led by expert faculty. Presented adjunct to the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer held in San Juan, Puerto Rico, this symposium provides an ideal forum for translating new clinical trial data, molecular insights, and evolving standards of care into real-world practice. The format is designed to help clinicians contextualize emerging evidence, compare decision-making with peers and experts, and strengthen their ability to personalize therapy for patients with LGSOC.
This educational activity is an archive of the live presentation held on Sunday, April 12, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward attendees of the SGO Annual Meeting on Women’s Cancer, including medical oncologists, radiation oncologists, pathologists, obstetrician/gynecologists, advanced practice providers, nurses, pharmacists, trainees, and other health care providers involved in the management of patients with ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better
prepared to:
- Describe key distinguishing features of low-grade serous ovarian cancer (LGSOC) to ensure accurate diagnosis
- Examine the current standard of care for LGSOC, focusing on the roles of surgery and adjuvant systemic therapies, including chemotherapy, targeted therapies, and hormonal therapies
- Develop personalized treatment plans for patients with recurrent LGSOC based on patient- and disease-specific characteristics
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here